J&J's Symtuza Will Debut In Europe On Cramped HIV Market

 
• By Lucie Ellis-Taitt

Johnson & Johnson's combination HIV therapy Symtuza has secured a greenlight in Europe, marking its first approval worldwide – but will the big pharma be able to catch up with successful HIV opponents from AbbVie and Gilead?

Parking lot full of cars
Symtuza enters crowded space • Source: Shutterstock

More from Anti-infective

More from Therapy Areas